Bladder Cancer, Bladder Disease, Bladder Pain Syndrome, Haemorrhagic Cystitis, Interstitial Cystitis, Intravesical Instillation, Recurrent Cystitis, Recurrent Urinary Tract Infections
Conditions
Keywords
intravesical therapy, catheterization, recurrent urinary tract infection, IC/BPS, Interstitial Cystitis/Bladder Pain syndrome, Post-chemotherapy Cystitis, Post-Irradiation Cystitis, Intravesical instillation, UroDapter
Brief summary
This study aims to evaluate a catheter-free method for delivering medications directly into the bladder, known as intravesical instillation, which is commonly used to treat conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent urinary tract infections, bladder cancer, and post-chemotherapy or post-radiation cystitis. The study investigates whether this method, which eliminates the need for catheterization, reduces discomfort and complications while maintaining treatment effectiveness. By collecting data on patient experiences and outcomes, the study seeks to determine if this approach provides a safer and more comfortable alternative to traditional catheter-based treatments.
Detailed description
Intravesical instillation, a method involving the direct administration of therapeutic agents into the bladder via a catheter, is widely used in the treatment of various urological conditions, including interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent urinary tract infections (UTIs), post-chemotherapy and post-radiation cystitis, and non-muscle invasive bladder cancer. This approach allows high concentrations of medication to be delivered directly to the bladder without systemic exposure, thereby enhancing treatment efficacy while reducing the risk of systemic side effects. A notable drawback of traditional intravesical treatments is the need for catheterization. However, catheter-free intravesical instillations have become possible with the use of a specialized urological adapter that requires only 6-8 mm insertion into the urethral opening (UroDapter). By relaxing the urethral sphincter, patients can facilitate the delivery of the instillation fluid into the bladder without a catheter. This method is painless, causes minimal discomfort, and significantly reduces the risk of urinary tract infections, urethral bleeding, and urethral strictures compared to catheter-based approaches. Catheter-free intravesical instillations have been performed in Hungarian outpatient urology settings since 2018. This prospective observational study includes patients whose physicians recommended catheter-free bladder instillation therapy. The study aims to anonymously collect data on the treatment's effectiveness, patient experience and incidence of complications associated with the caheter-free approach, focusing on its application for IC/BPS, recurrent UTIs, post-chemotherapy and post-radiation cystitis, and bladder cancer. Findings will be instrumental in refining protocols for intravesical treatments and enhancing patient compliance and satisfaction.
Interventions
DEVICECatheter-Free Intravesical Instillation with a special syringe adapter
The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
Sponsors
Jahn Ferenc South Pest Teaching Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male and female patients aged between 18 and 80 years. * Patients for whom the treating physician has determined that intravesical instillation is necessary due to one of the following conditions: * Interstitial cystitis/bladder pain syndrome (IC/BPS). * Recurrent urinary tract infections (UTIs). * Non-muscle invasive bladder cancer. * Post-radiation cystitis. * Post-chemotherapy cystitis. * Negative urine culture within the last two weeks. * Patients who provide verbal and written informed consent to participate in the study.
Exclusion criteria
* Urinary tract infection within the past month or currently active infection. * Diagnosed bleeding disorders or recurrent macroscopic hematuria. * Post-void residual urine volume greater than 100 ml. * Mental condition that prevents reliable cooperation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Discomfort During Catheter-Free Intravesical Instillation | Up to two weeks. | Level of discomfort experienced by patients during catheter-free intravesical instillation treatments, measured using the Numerical Rating Scale (NRS) from 0 to 10 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Success Rate of Catheter-Free Instillation | During each instillation visit. | Proportion of instillation procedures successfully completed as judged by the treating physician. |
| Incidence of Post-Treatment Urinary Tract Infections | Within 1-2 weeks following the last instillation. | Occurrence of urinary tract infections post-treatment, confirmed by symptoms and positive urine culture. |
| Incidence of Urethral Bleeding | Within 2 weeks following the last instillation. | Number of patients experiencing urethral bleeding during or after catheter-free intravesical instillation. |
| Patient Preference for Catheter-Free Instillation | Within 2 weeks following the last instillation. | Percentage of patients preferring catheter-free intravesical instillation compared to previous catheter-based treatments (only in the sub-group of pts who had previous catheter-based treatments). |
| Incidence of Other Post-Treatment Complications | Within 2 weeks following the last instillation. | Any additional complications related to catheter-free intravesical instillation, including pain or discomfort beyond expected levels. |
Countries
Hungary
Contacts
Primary ContactZoltan Balogh, Dr.
Outcome results
None listed